Sol-Gel Technologies Ltd. (SLGL): שולי רווח נקי ממכירות

Sol-Gel Technologies (SLGL) is implementing silica encapsulation for the sustained release of drug components, minimizing side effects in the treatment of rosacea. Net profit margins reflect the efficiency of this strategy, where -1115.40 is recorded as the baseline value. This innovative delivery system is redefining dermatological standards, while the current stage of business maturity relies on royalty collection and the expansion of its topical product line.
Sol-Gel Technologies (SLGL) - פילוחי מדדים ודוחות פיננסיים

Sol-Gel Technologies' high reputation in dermatology allows the company to maintain the premium status of its B2B contracts. This metric is calculated as the ratio of net income to total revenue, quantifying the final efficiency of operating activities. It demonstrates the portion of every dollar of revenue remaining after all deductions. Temporary drawdowns often signal investments in expansion rather than a crisis. By analyzing the net profit margin, an investor assesses the real resilience of the business.